Xiong ZM et al., 2015-12-14: The primary progeria paper: in Hutchinson-Gilford progeria syndrome fibroblasts, progerin caused swollen, fragmented and immobile mitochondria and suppressed PGC-1alpha, and 100 nM methylene blue for up to 12 weeks restored proliferation, nuclear morphology and heterochromatin and released progerin from the nuclear membrane.
Our analysis indicated that MB treatment not only alleviated the mitochondrial defects but also rescued the hallmark nuclear abnormalities in HGPS cells. Additional analysis suggested that MB treatment released progerin from the nuclear membrane
abstract
Xiong ZM et al., 2015-12-14: The primary progeria paper: in Hutchinson-Gilford progeria syndrome fibroblasts, progerin caused swollen, fragmented and immobile mitochondria and suppressed PGC-1alpha, and 100 nM methylene blue for up to 12 weeks restored proliferation, nuclear morphology and heterochromatin and released progerin from the nuclear membrane. Study type: in-vitro patient fibroblasts (HGPS-1 and HGPS-2 lines with the classic G608G LMNA mutation) plus normal fibroblast controls and lentiviral GFP-progerin expression. N: two HGPS lines, two normal lines. Country: USA (University of Maryland). Dose: methylene blue 100 nM in culture medium, from passage 14, for 8-12 weeks, refreshed with medium. Comparator: PBS vehicle. Funder: NHLBI R01 HL126784 and NIA R21 AG043801. Declared conflicts: none in the PubMed record; senior author Kan Cao is later disclosed as founder of Mblue Labs (see Xue et al. 2021, doc MTE-19). No animal or human dosing was tested. This confirms the Xiong citation the source uses: authors, journal, year and cell model are correctly identified in the claim. Study type: lab.
